Berg partners with Genomics England and eyes UK partners to establish new base

2 October 2015

Berg, the Boston-based biopharma company specializing in precision medicine is to join forces with Genomics England in the project to sequence 100,000 human genomes and create a new genomic medicine service for the UK by 2017.

Using biological profiling and Bayesian artificial intelligence, Berg is creating innovative drugs and processes in oncology.

Speaking to The Pharma Letter, Niven Narain, Berg’s chief executive, said: “With Genomics England, we will apply our analytics and methodologies to analyze and make sense of the data that will come out of the sequencing, and look at all the areas within the genomes that may present a risk.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK